IFNA1 and COVID-19: Patients with COVID-19 are being recruited in randomized trials to evaluate the efficacy of favipiravir plus IFN-α and favipiravir plus baloxavir marboxil (an approved influenza inhibitor targeting the cap-dependent endonuclease).